Vugmeyster, Yulia http://orcid.org/0000-0002-6289-2521
Grisic, Ana-Marija
Wilkins, Justin J.
Loos, Anja H.
Hallwachs, Roland
Osada, Motonobu
Venkatakrishnan, Karthik
Khandelwal, Akash
Funding for this research was provided by:
EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA
Article History
Received: 5 April 2022
Accepted: 17 August 2022
First Online: 6 September 2022
Declarations
:
: Y. Vugmeyster and K. Venkatakrishnan report employment and own stocks at EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA. A.-M. Grisic, A.H. Loos, R. Hallwachs, and A. Khandelwal report employment, royalties, and own stocks at Merck. J.J. Wilkins declares no potential conflicts of interest. M. Osada reports employment with Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA.
: All studies were conducted in accordance with the Good Clinical Practice guidelines as defined by the International Conference on Harmonisation and Declaration of Helsinki.
: All patients provided informed consent before starting treatment.